TIDMERGO

RNS Number : 4736K

Ergomed plc

29 August 2019

PRESS RELEASE

Notice of Interim Results

Guildford, UK - 29 August 2019: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2019 on 25 September 2019.

Miroslav Reljanović, Executive Chairman and Richard Barfield, Chief Financial Officer will host a presentation and conference call for analysts at 11am BST on the day of the results at the offices of Numis, 10 Paternoster Sq., London EC4M 7LT.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 1483 402 
                                                                         975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
 
 Numis Securities Limited                          Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for          Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Sue Stuart                      ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European               Tel: +49 211 5292 5222 
  enquiries 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORBLGDIRXDBGCI

(END) Dow Jones Newswires

August 29, 2019 02:01 ET (06:01 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.